Fruit Development, Structure, and Function
Self-Evaluation: Self-Enhancement and Self-Verification
Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability Enhancement: Drug Permeability Enhancement
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Sustainable Development
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 29, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
Julian N Ramos1, Katrin Hollinger2, Niclas E Bengtsson2
1Molecular and Cellular Biology Program, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Neurology, University of Washington School of Medicine, Seattle, WA 98195, USA; Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Seattle, WA 98195, USA.
Gene therapy for Duchenne muscular dystrophy (DMD) faces challenges with adeno-associated viral (AAV) vector size limits. Researchers developed improved micro-dystrophins (μDys) that enhance muscle function, with one variant advancing to clinical trials.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: